Cabot (NYSE:CBT) Upgraded at Zacks Research

Zacks Research upgraded shares of Cabot (NYSE:CBT) from a strong sell rating to a hold rating in a report released on Tuesday morning,Zacks.com reports.

Other equities analysts have also recently issued research reports about the company. Mizuho boosted their price objective on Cabot from $72.00 to $80.00 and gave the company an “outperform” rating in a report on Thursday, December 18th. Jefferies Financial Group reiterated a “buy” rating and set a $81.00 target price on shares of Cabot in a research report on Thursday, January 8th. UBS Group upped their price target on shares of Cabot from $65.00 to $74.00 and gave the stock a “neutral” rating in a report on Monday, January 12th. JPMorgan Chase & Co. reduced their price target on shares of Cabot from $75.00 to $54.00 and set an “underweight” rating on the stock in a research note on Friday, November 28th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Cabot in a report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $72.25.

Cabot Price Performance

CBT stock opened at $72.28 on Tuesday. The stock has a market cap of $3.82 billion, a PE ratio of 12.03, a P/E/G ratio of 3.74 and a beta of 0.89. Cabot has a 12 month low of $58.33 and a 12 month high of $89.16. The company has a 50-day moving average price of $67.93 and a 200 day moving average price of $71.76. The company has a current ratio of 1.61, a quick ratio of 1.08 and a debt-to-equity ratio of 0.50.

Cabot (NYSE:CBT) last announced its quarterly earnings data on Monday, November 3rd. The specialty chemicals company reported $1.70 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.72 by ($0.02). Cabot had a return on equity of 24.55% and a net margin of 8.91%.The firm had revenue of $899.00 million during the quarter, compared to the consensus estimate of $967.02 million. During the same period in the previous year, the business earned $1.80 EPS. The firm’s revenue for the quarter was down 10.2% on a year-over-year basis. Cabot has set its FY 2026 guidance at 6.000-7.00 EPS. Equities research analysts anticipate that Cabot will post 7.57 earnings per share for the current year.

Cabot Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, December 12th. Shareholders of record on Friday, November 28th were given a dividend of $0.45 per share. The ex-dividend date of this dividend was Friday, November 28th. This represents a $1.80 dividend on an annualized basis and a yield of 2.5%. Cabot’s dividend payout ratio (DPR) is 29.95%.

Hedge Funds Weigh In On Cabot

A number of hedge funds and other institutional investors have recently modified their holdings of CBT. Smartleaf Asset Management LLC increased its holdings in Cabot by 598.0% during the third quarter. Smartleaf Asset Management LLC now owns 349 shares of the specialty chemicals company’s stock valued at $27,000 after buying an additional 299 shares during the period. Elevation Point Wealth Partners LLC bought a new stake in Cabot during the 2nd quarter valued at $28,000. Parkside Financial Bank & Trust increased its holdings in shares of Cabot by 95.5% in the 2nd quarter. Parkside Financial Bank & Trust now owns 387 shares of the specialty chemicals company’s stock valued at $29,000 after acquiring an additional 189 shares during the period. Hantz Financial Services Inc. increased its holdings in shares of Cabot by 227.5% in the 3rd quarter. Hantz Financial Services Inc. now owns 429 shares of the specialty chemicals company’s stock valued at $33,000 after acquiring an additional 298 shares during the period. Finally, Geneos Wealth Management Inc. raised its position in shares of Cabot by 409.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 453 shares of the specialty chemicals company’s stock worth $38,000 after acquiring an additional 364 shares in the last quarter. 93.18% of the stock is currently owned by institutional investors.

About Cabot

Cabot Corporation is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company has grown into a diversified manufacturer with operations across North America, Europe, Asia and Latin America. Cabot serves a wide range of end markets, including automotive, industrial, energy, and consumer products, supplying essential ingredients that enhance performance, durability and functionality.

The company operates two primary segments: Reinforcement Materials and Performance Materials.